Company: REVB
Filing Date: 2025-03-06
Form Type: 10-K
Source: 0000950170-25-034584
Chunk: 261

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-03-06
Form: 10-K
Item: Item 8
Chunk 261
---
 that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and

•Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that our degree of compliance with the policies or procedures may deteriorate.

In connection with the preparation of this Annual Report, our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2024. In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control—Integrated Framework (2013 framework). Based on such assessment, our management concluded that, as of December 31, 2024, our internal control over financial reporting was effective based on those criteria.

 Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting that occurred during our most recent quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Item 9B. Other Information.

None.

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.

Not applicable.

 69

PART III

﻿ 

Item 10. Directors, Executive Officers and Corporate Governance. 

﻿ 

Executive Officers and Directors

The following table sets forth information regarding our executive officers and directors, including their ages as of March 3, 2025:

    Name
     
    Age
     
    Position

    BOARD OF DIRECTORS

    George Tidmarsh, M.D., Ph.D.
     
    65
     
    Chairman and Director

    James Rolke
     
    56
     
    Director and Chief Executive Officer

    Jennifer Carver, BSN, MBA
     
    71
     
    Director

    Jess Roper
     
    60
     
    Director

    Lakhmir Chawla, M.D.
     
    54
     
    Director

    EXECUTIVE OFFICERS

    James Rolke
     
    56
     
    Director and Chief Executive Officer

    Chester S. Zygmont, III